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Carotid artery atherosclerosis is a major factor in
the pathogenesis of focal cerebral ischemia1 and
accounts for a substantial number of deaths and
severe disability. Although the severity of stenosis is
associated with the risk of developing ipsilateral
ischemic symptoms, it is neither the sole determi-
nant of such risks nor the only factor influencing
whether the lesion becomes clinically significant.2-6
Plaques that are predominantly echolucent on B-
mode ultrasonography and that contain a high con-
tent of intraplaque hemorrhage or lipid are more
likely to produce symptoms, whereas those com-
posed primarily of fibrous tissue are echogenic, more
stable, and considered to be low-risk lesions.2,7-9
A number of studies have attempted to define
the histological features of an unstable carotid
plaque that are associated with the onset of ipsilater-
al cerebral ischemic symptoms. The histological fea-
tures considered include intraplaque hemorrhage,
the age and size of hemorrhage, the presence or
Macrophage accumulation within the cap
of carotid atherosclerotic plaques is
associated with the onset of cerebral
ischemic events
Tariq Husain, BSc, Cedric R. Abbott, FRCPath, D. Julian A. Scott, MD,
FRCS, and Michael J. Gough, ChM, FRCS, Leeds, United Kingdom
Purpose: Macrophage accumulation is associated with aortic and coronary plaque insta-
bility. The macrophage content of carotid plaques removed at carotid endarterectomy
(CE) was assessed, and the relevance to the onset of ipsilateral cerebral ischemic events
(CIE) was examined.
Methods: Carotid plaques from patients undergoing CE were examined (group I, symp-
tomatic stenoses, n = 28; group II, high-grade asymptomatic stenosis, n = 7). The
plaques were stained with monoclonal antimacrophage antibody (HAM56), and the
interval since the last CIE was recorded. The percentage area of the cap, shoulder, and
entire sclerotic region was quantified by computerized planimetry.
Results: The macrophage content of the cap, shoulder, and sclerotic region in all 35
plaques was 1.14% (interquartile range, 0.56 to 3.86), 1.03% (0.51 to 2.15), and 0.49%
(0.27 to 0.63), respectively (cap vs sclerotic, P < .01; shoulder vs sclerotic, P < .01; cap
vs shoulder, P = .23). In 18 plaques that were removed less than 180 days after the last
CIE, the macrophage content of the cap, shoulder, and entire sclerotic region was 2.41%
(0.95 to 4.81), 0.83% (0.40 to 2.52), and 0.53% (0.38 to 0.71), respectively (cap vs scle-
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interval since symptoms support the hypothesis that macrophage accumulation is asso-
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absence of plaque ulceration, mural thrombus, and
the amount and type of lipid within the plaque.10-14
No consensus has been reached as to which histo-
logical features are of significance.
In contrast, it has been established that mono-
cyte-derived macrophage and foam cell accumulation
within the plaque cap is associated with plaque insta-
bility and rupture in coronary and aortic lesions.15-17
Furthermore, abundant HLA-DR antigen expression
by these inflammatory cells indicates that an active
inflammatory process is present at these sites of insta-
bility.16 The aim of this study was to quantify 
the macrophage content of carotid plaques from
patients undergoing carotid endarterectomy (CE).
Furthermore, the data from this analysis was com-
pared with the time since the last ipsilateral cerebral
ischemic symptom to assess any temporal relationship
between these two variables. 
METHODS
Patients. CE specimens were obtained from 38
patients (26 men and 12 women; median age, 66
years; range, 46 to 84 years) undergoing CE. Of the
38 patients, 29 underwent surgery for symptomatic
carotid stenoses, seven underwent surgery for a
high-grade asymptomatic stenosis, and two under-
went staged bilateral procedures for unilateral symp-
tomatic disease and a contralateral asymptomatic
high-grade stenosis; thus, 31 symptomatic plaques
(group I) and nine asymptomatic plaques (group II)
were available for assessment. Routine cerebral com-
puterized tomography was not performed in these
patients, therefore, although the asymptomatic
patients had not experienced any neurological symp-
toms, it is not possible to exclude the possibility of a
previous silent cerebral infarct. The study was
approved by the hospital research ethics committees,
and informed consent was obtained.
The interval between the most recent ipsilateral
neurological symptom (stroke, transient ischemic
attack, or amaurosis fugax) and surgery was recorded
for all patients, as were risk factors for peripheral vas-
cular disease (current and past smoking status, hyper-
tension, diabetes mellitus, hypercholesterolemia, and
coronary artery disease).
Carotid endarterectomy specimens. After CE,
the fresh specimen was immediately fixed in 10%
buffered formalin and examined macroscopically to
assess the integrity of the plaque and the degree of
disruption. Of 40 surgical specimens, three were
heavily disrupted and were unsuitable for morpho-
metric analysis; these were excluded from the study.
The remaining specimens were decalcified in EDTA
for 48 hours, cut transversely at 2 mm intervals,
processed, and embedded in paraffin in accordance
with standard techniques. 
Sections from each block were stained with
hematoxylin and eosin (H&E) and elastic van Gieson
(EVG) and examined by a pathologist (C.R.A.), who
was blind to the clinical history, to assess the histo-
logical integrity of the specimen and determine its
suitability for formal assessment of the macrophage
content. In two specimens, substantial histological
disruption made accurate definition of the cap and
shoulder regions impossible; these plaques were
excluded from further analysis. Thus, 35 plaques
were suitable for full assessment (group I, n = 28;
group II, n = 7). 
Immunohistochemistry. At 2 mm intervals
throughout the plaque, 5-m m-thick serial sections
were cut from each of the paraffin blocks of the 35
suitable plaques, mounted on lysine-coated slides, and
stained with H&E, EVG, and monoclonal anti-
macrophage antibody (HAM56). The sections for
immunohistochemistry were deparaffinized in xylene,
rehydrated with graded alcohols, and preincubated
with 0.5% hydrogen peroxide in methanol. The sec-
tions were digested with freshly prepared 0.05%
trypsin solution at 37°C for 10 minutes, before incu-
bation with 10% goat serum and then HAM56 anti-
body (Dako, Cambridge, UK) at a dilution of 1 to 50.
HAM56 antibody specifically stains fixed tissue
macrophages, particularly within atherosclerotic tis-
sue. Immunolabeling was detected with a biotinylat-
ed secondary antibody and an avidin-biotin-peroxi-
dase complex (Dako Duet, Dako, Cambridge, UK)
and visualized with diaminobenzidine. Sections of
carotid plaque in which the primary antibody was
omitted were run concurrently and served as negative
controls. Aortic aneurysm tissue, which contained an
abundance of macrophages, was included as positive
control material. 
Macrophage quantification. Images of the
plaques were acquired by using a trinocular light
microscope (Dialux 20EB, Leica, Milton Keynes,
UK) or a dissecting microscope (Wild MZ8, Leica,
Milton Keynes, UK), via a color video camera (TK-
1280, JVC, Japan), and the macrophage content
was quantified by means of computerized planime-
try with the Qwin image analysis package (Leica
Imaging Systems, Cambridge, UK; Fig 1). These
measurements were performed “blind,” although
the technique eliminates any operator influence on
the results. The macrophage content within the cap,
shoulders, and the entire sclerotic component were
analyzed separately. The sclerotic component was
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considered to be all the nonlipid, nonthrombotic
material found within the bounds of the internal
elastic lamina and included the cap and shoulder
regions. The cap was defined as the fibrous tissue
between the lipid core and the vessel lumen, and the
shoulder regions were defined as the tissue immedi-
ately adjacent to the cap and lipid core (Fig 2). 
Within each tissue block, the histological com-
ponents of the plaque were defined by using the
H&E- and EVG-stained sections, permitting the
area occupied by stained macrophages within each
component to be quantified. HAM56 antibody
specifically stains the cytoplasm of the cells and thus
enabled the total positively stained area to be used as
a measure of the tissue macrophage content. The
percentage of each histological plaque component
occupied by macrophages was calculated by averag-
ing the results from all the sections cut from each
plaque—as many as eight slides per tissue block.
Statistical analysis. Results are expressed as the
median (interquartile range [iqr]); probability values
less than .05 were considered significant. For compar-
ison of the clinical and demographic data, Mann-
Whitney and Fisher exact tests were used. Wilcoxon
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Fig 1. Electronically acquired light microscopic images illustrating the computer-aided morpho-
metric analysis of the macrophage content. A, Tissue section of carotid atherosclerotic plaque
removed at endarterectomy stained with monoclonal antimacrophage antibody (HAM56). There
are a number of artefactual creases within the tissue section (original magnification, 285 · ). 
B, Computerized representation of the tissue staining (shown in blue) demonstrating the excel-
lent specificity for the macrophage staining while excluding the tissue artefacts.
A
B
signed rank tests were used to compare the macro-
phage content within each of the three histological
plaque components. Pearson correlation coefficients
and Mann-Whitney tests were performed to compare
the time since the last ipsilateral symptom with the
macrophage content of the plaques. 
RESULTS
Morphometric assessment was performed on 35
carotid plaques. Twenty-eight plaques were obtained
from symptomatic patients (group I), and seven were
obtained from asymptomatic patients (group II). Of
the group I plaques, the median interval between
symptoms (14 transient ischemic attacks and eight
completed strokes in the territory of the relevant
middle cerebral artery, six amaurosis fugax) and
endarterectomy was 99 days (range, 15 to 246 days).
Comparison of the demographic details of the two
groups did not show any significant differences
(Table I). The two patients who underwent bilateral
CE were excluded from this comparison, because
both patients had one symptomatic and one asymp-
tomatic carotid plaque removed. 
Macrophage content of the different histo-
logical components of plaques. When the results
from all 35 plaques were considered together, there
was a significant difference between the macrophage
content of the sclerotic component and the cap
(0.49% [0.27 to 0.63] vs 1.14% [0.56 to 3.86]; z =
–3.72, P < .01), and the sclerotic component and
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Fig 2. A, Electronically acquired light microscopic image of a section of carotid atherosclerotic
plaque removed at carotid endarterectomy (original magnification, 45 · ; elastic van Gieson’s
stain). B, Schematic representation showing the regions of the atherosclerotic plaque that were
defined as the lipid core, fibrous cap, and shoulders components.
A
B
shoulder regions (0.49% [0.27 to 0.63] vs 1.03%
[0.51 to 2.15]; z = –3.67, P < .01). There was, how-
ever, no significant difference between the
macrophage content of the cap and shoulder com-
ponents (z = –1.20, P = 0.23). When the compari-
son was restricted to group I plaques, the difference
between the sclerotic component and the other two
components remained, whereas the difference
between the cap and shoulder regions again failed to
achieve statistical significance (Table II). 
Earlier randomized trials that assessed the role of
CE in symptomatic patients with a critical carotid
stenosis have suggested that plaques should be con-
sidered symptomatic only within 180 days of the last
cerebral ischemic event.4,5 When the plaques avail-
able for assessment were reclassified according to
this definition, comparison of the macrophage con-
tent of the cap and shoulder regions of plaques
removed within this time limit (group III, n = 18)
demonstrated a significant difference: 2.41% (0.95
to 4.81) versus 0.83% (0.40 to 2.52; z = –2.46, P =
.01). Similar differences occurred between the scle-
rotic and cap macrophage content in these patients
(0.53% [0.38 to 0.71] vs 2.42% [0.95 to 4.81]; z =
–2.72, P = .01), but not when the content of the
sclerotic and shoulder regions was compared (z =
–1.72, P = .09).
Macrophage content of plaques and symptoms.
To examine the possibility that the macrophage con-
tent of the sclerotic, cap, or shoulder components was
related to the time since the onset of symptoms,
Pearson correlation coefficients were calculated for
these parameters for the patients in group I. These
were r = –0.215, P = 0.272 for the sclerotic compo-
nent; r = –0.414, P = 0.029 for the cap component;
and r = 0.164, P = 0.406 for the shoulder component.
Thus, patients with more recent symptoms demon-
strated a higher macrophage content within the cap
component of their plaques. The results for cap
macrophage content are shown in Fig 3.
Furthermore, when the macrophage content of
group I plaques was compared with that of group II
plaques, the cap macrophage content was shown to
be significantly greater (1.28% [0.69 to 4.28] vs
0.57% [0.43 to 0.71]; z = –2.14, P = .03). No dif-
ferences were found when the sclerotic (0.51% [0.41
to 0.65] vs 0.27% [0.11 to 0.55]; z = –1.44, P = .15)
or shoulder (1.11% [0.46 to 2.33] vs 0.97% [0.73 to
2.04]; z = –0.04, P = .97) components of group I
and group II plaques were compared.
Comparison of the macrophage content of those
plaques removed within 180 days of the last cerebral
ischemic event (group III, n = 18) with either those
removed after this time limit or those that had
always been asymptomatic (group IV, n = 17) indi-
cated that cap macrophage content was significantly
higher in the former group (2.41% [0.95 to 4.81] vs
0.62% [0.44 to 1.25]; z = –2.54, P = .01). There
were no differences between these groups in respect
to the sclerotic (0.53% [0.38 to 0.71] vs 0.48%
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Table I. Clinical and demographic characteristics of patients included within the study, excluding the two
patients undergoing bilateral carotid endarterectomy
Characteristic Symptomatic (n = 26) Asymptomatic (n = 5) P
Median age in years (iqr) 66.5 (63 to 75) 66 (63 to 68) .44
Men 17 (65.4%) 4 (80%) .94
Current smoking 12 (46.2%) 1 (20%) .57
Current or previous smoking 19 (73.1%) 4 (80%) 1
Hypertension 12 (46.2%) 4 (80%) .37
Diabetes mellitus 4 (15.4%) 1 (20%) 1
Hypercholesterolemia 5 (19.2%) 3 (60%) .19
Coronary artery disease 12 (46.2%) 2 (40%) 1
iqr, Interquartile range.
Table II. Macrophage content (median + interquartile range) of the different histological components of
the symptomatic plaques
Sclerotic component Cap Shoulders
0.51% (0.41 to 0.65) 1.28% (0.69 to 4.28) 1.11% (0.46 to 2.33)
z = –3.42, P < .01 z = –1.78, P = .076
z = –2.96, P < .01
[0.20 to 0.61]; z = –1.29, P = .20) or shoulder
(0.83% [0.40 to 2.52] vs 1.19% [0.84 to 1.95]; z =
0.56, P = 0.57) components. 
DISCUSSION
Previous studies examining acute changes in
coronary plaques have indicated that disruption of
the fibrous cap is associated with infiltration by acti-
vated macrophages and, thus, an active inflammato-
ry process.16 It has been suggested that these
macrophages are involved in the onset of plaque
instability and, thus, the pathogenesis of acute coro-
nary events. The aim of our study was to quantify
the macrophage content of human carotid plaques
removed during CE, with the hypothesis that a sim-
ilar accumulation of macrophages may be associated
with the onset of cerebral ischemic events.
The results have indicated a marked accumulation
of macrophages within both the cap and shoulder
regions of carotid plaques, with this accumulation
being maximal within the cap. This observation was
confirmed when all 35 plaques were studied and
when the analysis was restricted to plaques removed
from previously symptomatic patients (group I) or
just those defined as symptomatic by the European
Carotid Surgery Trial (ECST) and North Ameri-
can Symptomatic Carotid Endarterectomy Trial
(NASCET; group III).4,5 Thus, although the sample
size is relatively small, the findings are consistent. This
data provides the first quantification of macrophage
accumulation in such plaques, substantiating previous
semiquantitative data.18,19 Furthermore, the results
indicate that cap macrophage infiltration is greatest
within the plaques of those patients with recent ipsi-
lateral cerebral ischemic symptoms. This is particular-
ly striking when the ECST/NASCET criteria4,5 are
used to define the symptomatic status of the patient
(group III). 
The association between macrophage accumulation
and the time since the last ipsilateral symptom is only
significant within the cap component of the plaques.
No temporal relationship was found when either the
shoulder regions or the entire sclerotic component
were considered. This suggests that recently sympto-
matic patients do not have an increased plaque
macrophage content per se, but that there is a focal
accumulation of macrophages within the cap, which is
only one part of the sclerotic component. This quanti-
tative data supports the work of previous authors,
which suggested that macrophage infiltration of carotid
plaques was associated with plaque rupture and fibrous
cap thinning.20 These microscopic morphological fea-
tures have not been used to assess plaque instability in
the present study, although it may be of interest to
compare the results of immunohistochemical quantifi-
cation of macrophage content with these features. 
The results from the present study conflict with
the study of coronary lesions by Moreno et al, who
reported that macrophage content was increased in
the sclerotic component as a whole in patients with
acute coronary syndromes.17 However, macro-
phage content was determined in fragments of
plaque obtained at coronary atherectomy in that
study, in which it would have been more difficult to
accurately define the components of the specimens.
In contrast, we examined the entire endarterectomy
specimen and accurately defined the different
anatomical regions of the plaque. Therefore, the
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Fig 3. Scatter-plot of cap macrophage content versus the elapsed time between the last symptom
and ipsilateral endarterectomy in symptomatic patients.
present study should be more accurate in defining
the location of macrophages within the plaque, and
it is likely that the discrepancy between the studies
reflects differences in methodology. Alternatively,
the different results may reflect a true variation in
the histopathology of unstable carotid and coronary
lesions, which is perhaps attributable to differences
in vessel caliber.
The precise temporal relationship between
macrophage accumulation and plaque disruption is
uncertain. Macrophage infiltration of carotid plaques
may not be the cause of plaque instability, but rather
the consequence. Certainly our data could be inter-
preted in this way, because those plaques with clinical
evidence of recent instability exhibited the greatest
macrophage content. Although none of the sympto-
matic plaques contained entrapped leukocytes, which
may have indicated a pathophysiological role for the
accumulated macrophages, we concede that the min-
imum duration between the last ipsilateral neurolog-
ical symptoms and CE was five days. Thus, this
observation may be of little significance. However, all
the plaques did exhibit a chronic inflammatory reac-
tion, which provides some evidence that the cellular
infiltrate was present before the onset of cerebral
ischemic symptoms. 
Although this hypothesis would be consistent
with the findings in most carotid plaques that were
examined, a substantial accumulation of macrophages
within the cap was observed in two of the plaques that
had not been recently symptomatic and would have
been classified as asymptomatic in the NASCET and
ECST trials. Despite our examining further, deeper,
and more widespread sections of these plaques, there
was no evidence of rupture or hemorrhage in either
specimen. It is possible that these lesions were pro-
gressing towards instability and may have caused
symptoms in the near future, thus supporting our
belief that macrophages are indeed the precursors of
plaque instability. Such a claim cannot be substantiat-
ed, however. 
If macrophage infiltration promotes plaque
instability and thus plaque rupture, the mechanisms
by which this could occur must be considered.
Macrophages secrete a number of proteases, includ-
ing the metalloproteinases and cathepsin S, that will
actively degrade the components of the arterial
extracellular matrix, thereby weakening the plaque’s
fibrous capsule and promoting plaque disrup-
tion.21-25 Moreover, macrophages, via an interaction
with T-lymphocytes, may also reduce the fibrous
content of plaque caps by reducing its synthesis,
either by inhibiting proliferation of or promoting
apoptosis of vascular smooth muscle cells (VSMCs),
which are the principal source of fibrous tissue.26,27
Recently, work in coronary lesions has focused on
the role of tissue factor (TF) in the clinical presenta-
tion of plaque rupture. TF is a potent initiator of
intravascular thrombogenesis and, as such, enhances
the thrombogenicity of disrupted atherosclerotic
plaques.28 Furthermore, recent studies have indicated
that macrophages are the principal source of TF with-
in atherosclerotic plaques.29,30 Thus, macrophages
may not only influence the integrity of the fibrous cap
and the propensity to plaque disruption, but also pro-
mote thrombosis after plaque rupture. 
Although macrophages appear to have a major
role in promoting plaque instability, other cellular
components may also be important. There is increas-
ing evidence to suggest that both T-cells and VSMCs
may have a significant influence on these events. T-
cells localize at sites of plaque rupture16 and have
been shown to be capable of influencing the function
of both macrophages and VSMCs, via cytokine and
CD40 ligand pathways.31-34 VSMCs have been
implicated in the pathophysiology of plaque disrup-
tion and its consequences, both because of their role
in maintaining the integrity of the fibrous cap and
also because of their ability to express both metallo-
proteinases and TF.16,20,21,30,34
In conclusion, not only are macrophages a consti-
tutive component of carotid atherosclerotic plaques,
but their accumulation within the shoulder and, in
particular, the cap regions appears to be related to the
pathogenesis of carotid plaque instability and, thus,
the onset of cerebral ischemic symptoms. 
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